Tugce Apaydin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Tugce Apaydin has a total of 103 co-authors. Here are the top co-authors by number of shared publications:
- Dilek Gogas Yavuz
Department of Endocrinology and Metabolism, Marmara University Faculty of Medicine, Istanbul, Turkey
14 shared publications - Can Ilgin
Radiation Oncology Department, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey
5 shared publications Dilek Gogas Yavuz
Marmara Universitesi Tip Fakultesi
5 shared publications- Goncagul Haklar
Department of Biochemistry, School of Medicine, Marmara University, Istanbul, Turkey
5 shared publications - Onur Elbasan
Department of Endocrinology and Metabolism Marmara University School of Medicine Istanbul Turkey
5 shared publications - Ceyda Dincer Yazan
Marmara University School of Medicine, Department of Endocrinology and Metabolism 1
4 shared publications
Latest Publications
- Open Access
- 13 November 2026
- Published by Bioscientifica in Endocrine Connections
Hepatic Steatosis in Primary Aldosteronism, Cushing’s Syndrome, and Mild Autonomous cortisol secretion: Metabolic and Hormonal Associations
Context: Metabolic dysfunction–associated steatotic liver disease (MASLD) is closely linked to obesity, diabetes mellitus (DM), and dyslipidemia. Patients with primary aldosteronism (PA), Cushing’s syndrome (CS) and mild autonomous cortisol secretion (MACS) exhibit metabolic abnormalities, but the relative contributions of hormonal and metabolic factors to hepatic steatosis remain unclear. Objective: To evaluate MASLD prevalence and determinants in PA, CS, and MACS. Design: Single-center retrospective cross-sectional study. Methods: 243 treatment-naive patients underwent unenhanced abdominal computed tomography: 102 isolated PA, 60 CS, 47 MACS, and 34 PA with cortisol co-secretion. Hepatic steatosis was assessed using liver-to-spleen (L/S) attenuation ratio. Hepatic steatosis index (HSI), and triglyceride–glucose (TyG) index were calculated. Results: MASLD prevalence was 28.4% in isolated PA, 26.6% in CS, 31.9% in MACS and 26.4% in PA with cortisol co-secretion. Liver attenuation and L/S ratio were similar across groups but correlated with visceral adiposity, glucose, HbA1c, triglycerides, HSI, and TyG index (all r>0.5, p<0.05). DM was independently associated with lower liver attenuation after adjustment for age, sex, and BMI (β = −11.10 HU, 95% CI: −16.40 to −5.79). Serum cortisol, cortisol after the 1-mg DST, aldosterone, and renin were not independently associated with hepatic steatosis, whereas UFC was independently associated with the L/S attenuation ratio in the hypercortisolism subgroup. Conclusions: Hepatic steatosis was similarly prevalent across PA, CS, and MACS, and was associated with metabolic factors, particularly DM, BMI, visceral adiposity, and hypertriglyceridemia. These findings support consideration of hepatic steatosis assessment in patients with functional adrenal disorders and metabolic risk factors.
- 13 November 2026
- Published by Bioscientifica in Endocrine Connections
Open AccessHepatic Steatosis in Primary Aldosteronism, Cushing’s Syndrome, and Mild Autonomous cortisol secretion: Metabolic and Hormonal Associations
Context: Metabolic dysfunction–associated steatotic liver disease (MASLD) is closely linked to obesity, diabetes mellitus (DM), and dyslipidemia. Patients with primary aldosteronism (PA), Cushing’s syndrome (CS) and mild autonomous cortisol secretion (MACS) exhibit metabolic abnormalities, but the relative contributions of hormonal and metabolic factors to hepatic steatosis remain unclear. Objective: To evaluate MASLD prevalence and determinants in PA, CS, and MACS. Design: Single-center retrospective cross-sectional study. Methods: 243 treatment-naive patients underwent unenhanced abdominal computed tomography: 102 isolated PA, 60 CS, 47 MACS, and 34 PA with cortisol co-secretion. Hepatic steatosis was assessed using liver-to-spleen (L/S) attenuation ratio. Hepatic steatosis index (HSI), and triglyceride–glucose (TyG) index were calculated. Results: MASLD prevalence was 28.4% in isolated PA, 26.6% in CS, 31.9% in MACS and 26.4% in PA with cortisol co-secretion. Liver attenuation and L/S ratio were similar across groups but correlated with visceral adiposity, glucose, HbA1c, triglycerides, HSI, and TyG index (all r>0.5, p<0.05). DM was independently associated with lower liver attenuation after adjustment for age, sex, and BMI (β = −11.10 HU, 95% CI: −16.40 to −5.79). Serum cortisol, cortisol after the 1-mg DST, aldosterone, and renin were not independently associated with hepatic steatosis, whereas UFC was independently associated with the L/S attenuation ratio in the hypercortisolism subgroup. Conclusions: Hepatic steatosis was similarly prevalent across PA, CS, and MACS, and was associated with metabolic factors, particularly DM, BMI, visceral adiposity, and hypertriglyceridemia. These findings support consideration of hepatic steatosis assessment in patients with functional adrenal disorders and metabolic risk factors.
- 6 May 2026
- Published by Springer Nature in Journal of Endocrinological Investigation
- Vol. 49 (8) , 1871-1880
Metabolic dysfunction-associated steatotic liver disease in cushing’s syndrome: a case controlled FibroScan study
Metabolic dysfunction-associated steatotic liver disease (MASLD) is commonly associated with obesity, insulin resistance, and type 2 diabetes mellitus (T2DM). Cushing's syndrome (CS), defined by chronic hypercortisolism, shares overlapping metabolic features with MASLD. However, the relationship between CS and MASLD remains underexplored. This study aimed to investigate the prevalence of hepatic steatosis and fibrosis in patients with CS using FibroScan and to examine their relationship with clinical and metabolic parameters. This cross-sectional study included 44 patients with endogenous CS, along with 52 age-, sex-, and BMI-matched controls and 44 age- and sex-matched controls. Hepatic steatosis and fibrosis were assessed by controlled attenuation parameter (CAP) and liver stiffness measurement (LSM) using vibration-controlled transient elastography. MASLD was present in 56.8% of CS patients, with moderate-to-severe steatosis in 47.7%. CAP and LSM values were comparable between CS and metabolically matched controls, but CAP was higher than in healthy controls. CAP positively correlated with body mass index (BMI), waist circumference, triglycerides, and 24-hour urine cortisol (UFC), and negatively with growth hormone. LSM was positively correlated with BMI and GGT. No correlations were found with fasting glucose, HbA1c, or serum cortisol. Multivariate analysis identified UFC as an independent predictor of CAP, while BMI and GGT independently predicted LSM. Hepatic steatosis was frequent in CS and similar to metabolically matched individuals, but more common than in healthy controls. UFC, BMI, and waist circumference contribute to liver fat accumulation, while diabetes was not an independent predictor of steatosis in CS.
- 6 May 2026
- Published by Springer Nature in Journal of Endocrinological Investigation
- Vol. 49 (8) , 1871-1880
Metabolic dysfunction-associated steatotic liver disease in cushing’s syndrome: a case controlled FibroScan study
Metabolic dysfunction-associated steatotic liver disease (MASLD) is commonly associated with obesity, insulin resistance, and type 2 diabetes mellitus (T2DM). Cushing's syndrome (CS), defined by chronic hypercortisolism, shares overlapping metabolic features with MASLD. However, the relationship between CS and MASLD remains underexplored. This study aimed to investigate the prevalence of hepatic steatosis and fibrosis in patients with CS using FibroScan and to examine their relationship with clinical and metabolic parameters. This cross-sectional study included 44 patients with endogenous CS, along with 52 age-, sex-, and BMI-matched controls and 44 age- and sex-matched controls. Hepatic steatosis and fibrosis were assessed by controlled attenuation parameter (CAP) and liver stiffness measurement (LSM) using vibration-controlled transient elastography. MASLD was present in 56.8% of CS patients, with moderate-to-severe steatosis in 47.7%. CAP and LSM values were comparable between CS and metabolically matched controls, but CAP was higher than in healthy controls. CAP positively correlated with body mass index (BMI), waist circumference, triglycerides, and 24-hour urine cortisol (UFC), and negatively with growth hormone. LSM was positively correlated with BMI and GGT. No correlations were found with fasting glucose, HbA1c, or serum cortisol. Multivariate analysis identified UFC as an independent predictor of CAP, while BMI and GGT independently predicted LSM. Hepatic steatosis was frequent in CS and similar to metabolically matched individuals, but more common than in healthy controls. UFC, BMI, and waist circumference contribute to liver fat accumulation, while diabetes was not an independent predictor of steatosis in CS.
- Open Access
- 20 February 2026
- Published by Springer Nature in Journal of Endocrinological Investigation
- Vol. 49 (5) , 1029-1038
The relationship between acromegaly and hepatic steatosis: insights from FibroScan imaging
Purpose: The relationship between metabolic dysfunction-associated steatotic liver disease (MASLD) and acromegaly is unclear due to the complex metabolic effects of growth hormone (GH). GH stimulates gluconeogenesis, glycogenolysis, and lipolysis, increasing free fatty acids, a risk factor for MASLD, but may also protect against hepatic fat accumulation. In this study, we aimed to evaluate the impact of acromegaly and GH levels on liver steatosis and fibrosis using non-invasive FibroScan imaging. Methods: This cross-sectional study included 58 patients with acromegaly, 61 age- and sex-matched metabolically comparable controls, and 82 healthy controls. Hepatic steatosis and fibrosis were assessed via controlled attenuation parameter (CAP) and liver stiffness measurement (LSM) by vibration-controlled transient elastography. Moderate to severe steatosis was defined as CAP > 260 dB/m, and significant fibrosis as LSM ≥ 8.0 kPa. Results: Both acromegaly patients and metabolically healthy individuals exhibited lower CAP (241.8 ± 50.0 and 231.7 ± 51.9 dB/m) and LSM (4.7 ± 1.4 and 4.8 ± 1.8 kPa) scores than metabolically matched controls (CAP 281.7 ± 61.2 dB/m; LSM 5.5 ± 1.8 kPa; CAP p < 0.001; LSM p = 0.012). Moderate-to-severe steatosis was observed in 36.2% of acromegaly patients, 27.7% of healthy individuals, and 68.8% of metabolically matched controls ( p < 0.001), while significant liver fibrosis occurred in 5.2%, 7.3%, and 14.7%, respectively ( p = 0.154). GH levels were lower in acromegaly patients with MASLD ( p < 0.001) compared to those without. CAP correlated negatively with GH and positively with BMI, waist circumference, and triglycerides, whereas LSM correlated positively with age, BMI, and triglycerides. Conclusions: Hepatic steatosis was less frequent in acromegaly than in metabolically comparable individuals, and GH was inversely associated with hepatic steatosis scores, possibly suggesting a protective role of GH independent of metabolic comorbidities.
- 20 February 2026
- Published by Springer Nature in Journal of Endocrinological Investigation
- Vol. 49 (5) , 1029-1038
Open AccessThe relationship between acromegaly and hepatic steatosis: insights from FibroScan imaging
Purpose: The relationship between metabolic dysfunction-associated steatotic liver disease (MASLD) and acromegaly is unclear due to the complex metabolic effects of growth hormone (GH). GH stimulates gluconeogenesis, glycogenolysis, and lipolysis, increasing free fatty acids, a risk factor for MASLD, but may also protect against hepatic fat accumulation. In this study, we aimed to evaluate the impact of acromegaly and GH levels on liver steatosis and fibrosis using non-invasive FibroScan imaging. Methods: This cross-sectional study included 58 patients with acromegaly, 61 age- and sex-matched metabolically comparable controls, and 82 healthy controls. Hepatic steatosis and fibrosis were assessed via controlled attenuation parameter (CAP) and liver stiffness measurement (LSM) by vibration-controlled transient elastography. Moderate to severe steatosis was defined as CAP > 260 dB/m, and significant fibrosis as LSM ≥ 8.0 kPa. Results: Both acromegaly patients and metabolically healthy individuals exhibited lower CAP (241.8 ± 50.0 and 231.7 ± 51.9 dB/m) and LSM (4.7 ± 1.4 and 4.8 ± 1.8 kPa) scores than metabolically matched controls (CAP 281.7 ± 61.2 dB/m; LSM 5.5 ± 1.8 kPa; CAP p < 0.001; LSM p = 0.012). Moderate-to-severe steatosis was observed in 36.2% of acromegaly patients, 27.7% of healthy individuals, and 68.8% of metabolically matched controls ( p < 0.001), while significant liver fibrosis occurred in 5.2%, 7.3%, and 14.7%, respectively ( p = 0.154). GH levels were lower in acromegaly patients with MASLD ( p < 0.001) compared to those without. CAP correlated negatively with GH and positively with BMI, waist circumference, and triglycerides, whereas LSM correlated positively with age, BMI, and triglycerides. Conclusions: Hepatic steatosis was less frequent in acromegaly than in metabolically comparable individuals, and GH was inversely associated with hepatic steatosis scores, possibly suggesting a protective role of GH independent of metabolic comorbidities.
- Open Access
- 31 January 2024
- Published by Wiley
Prevalence of vitamin D deficiency and hypervitaminosis D among adult patients admitted to the tertiary care hospitals in Turkey
Purpose: Vitamin D deficiency is a common health problem around the world. This study aimed to evaluate the nationwide prevalence of vitamin D status in tertiary care hospitals in Turkey. Methods: Retrospectively, the data of vitamin D levels from 33 tertiary care hospitals’ clinical biochemistry laboratories around Turkey between 2 January 2016 and 31 December 2016 were conducted. Results: In total 706434 serum samples from adult subjects (F/M: 469028/ 237406; 66.4%/ 33.6%) were included. While vitamin D levels were sufficient in 20.3% (n=14222), they were insufficient in 21.9% (n=154360) and deficient in 57.8% (n=408882). Of the deficient group, 25.0% (176608) had levels <10 ng/mL consistent with profound deficiency. We observed the highest rates of deficiency in those aged between 18-29 years 62.9% (n=70235) and lowest rates in 60-69 years (52.3%, n=61121) and in 70-79 years (52.3%, n=32397). Hypervitaminosis D were consisting of 5.5% of adult subjects. highest rates of hypervitaminosis D were observed in over 80 years (6.6%) and 70-79 years (6.5%), and the lowest in 18-29 years (2.8%). Deficiency rates were 55.4% (n=131468) in men and 59.2% (n=277384) in women. Higher deficiency rates were observed in January (67.9%), February (71.6%), and March (66.7%). Conclusion: In this cohort, over half of the subjects admitted to the tertiary care hospitals in Turkey had vitamin D deficiency, required vitamin D supplementation. The elderly population had the lowest prevalence of vitamin D insufficiency and the highest prevalence of hypervitaminosis D. That may indicate overtreatment of vitamin D supplementation in the elderly group.
- 31 January 2024
- Published by Wiley
Open AccessPrevalence of vitamin D deficiency and hypervitaminosis D among adult patients admitted to the tertiary care hospitals in Turkey
Purpose: Vitamin D deficiency is a common health problem around the world. This study aimed to evaluate the nationwide prevalence of vitamin D status in tertiary care hospitals in Turkey. Methods: Retrospectively, the data of vitamin D levels from 33 tertiary care hospitals’ clinical biochemistry laboratories around Turkey between 2 January 2016 and 31 December 2016 were conducted. Results: In total 706434 serum samples from adult subjects (F/M: 469028/ 237406; 66.4%/ 33.6%) were included. While vitamin D levels were sufficient in 20.3% (n=14222), they were insufficient in 21.9% (n=154360) and deficient in 57.8% (n=408882). Of the deficient group, 25.0% (176608) had levels <10 ng/mL consistent with profound deficiency. We observed the highest rates of deficiency in those aged between 18-29 years 62.9% (n=70235) and lowest rates in 60-69 years (52.3%, n=61121) and in 70-79 years (52.3%, n=32397). Hypervitaminosis D were consisting of 5.5% of adult subjects. highest rates of hypervitaminosis D were observed in over 80 years (6.6%) and 70-79 years (6.5%), and the lowest in 18-29 years (2.8%). Deficiency rates were 55.4% (n=131468) in men and 59.2% (n=277384) in women. Higher deficiency rates were observed in January (67.9%), February (71.6%), and March (66.7%). Conclusion: In this cohort, over half of the subjects admitted to the tertiary care hospitals in Turkey had vitamin D deficiency, required vitamin D supplementation. The elderly population had the lowest prevalence of vitamin D insufficiency and the highest prevalence of hypervitaminosis D. That may indicate overtreatment of vitamin D supplementation in the elderly group.
- 5 October 2022
- Published by Elsevier in Microvascular Research
- Vol. 145, 104444
Capillary microarchitectural changes are independent of disease activity in acromegaly
- 5 October 2022
- Published by Elsevier in Microvascular Research
- Vol. 145, 104444
Capillary microarchitectural changes are independent of disease activity in acromegaly
- 1 July 2022
- Published by Elsevier in Journal of Clinical Densitometry
- Vol. 25 (3) , 373-379
Skin autofluorescence Is associated With low bone mineral density in type 2 diabetic patients
- 1 July 2022
- Published by Elsevier in Journal of Clinical Densitometry
- Vol. 25 (3) , 373-379
Skin autofluorescence Is associated With low bone mineral density in type 2 diabetic patients
- 4 April 2022
- Published by Springer Nature in European Spine Journal
- Vol. 31 (9) , 2423-2430
Clinical predictors of incipient vertebral fractures and bone mineral density in kidney transplant patients
Purpose Kidney transplant recipients are prone to metabolic bone diseases and consequent fractures. This study aimed to evaluate the incidence of incipient vertebral fractures, osteopenia, osteoporosis, and the clinical factors associated with incipient vertebral fractures in a group of kidney transplant patients. Methods Two hundred sixty-four patients (F/M 124/140, 45.3 ± 13 years) who had undergone kidney transplantation in tertiary care centers were included. Vertebral fractures were assessed semiquantitatively using conventional thoracolumbar lateral radiography in 202 of the patients. Results Vertebral fractures were observed in 56.4% (n = 114) of the study group. The frequency of osteoporosis was 20.0% (53 of 264 patients), and osteopenia was 35.6% (94 of 264 patients). Bone mineral density (BMD) levels were in the normal range in 40.3% (n = 46) of the subjects with vertebral fractures. It was in the osteoporotic range in 20.1% (n = 23) and the osteopenic range in 40.3% (n = 46). Vertebral fractures were associated with age, duration of hemodialysis, BMI, and femoral neck Z score (R2 37.8%, p = 0.027). Conclusion As incipient vertebral fractures can be observed in patients with normal BMD levels in kidney transplant recipients, conventional X-ray screening for vertebral fractures may be beneficial for a proper therapy decision of metabolic bone disease in kidney transplant recipients.
- 4 April 2022
- Published by Springer Nature in European Spine Journal
- Vol. 31 (9) , 2423-2430
Clinical predictors of incipient vertebral fractures and bone mineral density in kidney transplant patients
Purpose Kidney transplant recipients are prone to metabolic bone diseases and consequent fractures. This study aimed to evaluate the incidence of incipient vertebral fractures, osteopenia, osteoporosis, and the clinical factors associated with incipient vertebral fractures in a group of kidney transplant patients. Methods Two hundred sixty-four patients (F/M 124/140, 45.3 ± 13 years) who had undergone kidney transplantation in tertiary care centers were included. Vertebral fractures were assessed semiquantitatively using conventional thoracolumbar lateral radiography in 202 of the patients. Results Vertebral fractures were observed in 56.4% (n = 114) of the study group. The frequency of osteoporosis was 20.0% (53 of 264 patients), and osteopenia was 35.6% (94 of 264 patients). Bone mineral density (BMD) levels were in the normal range in 40.3% (n = 46) of the subjects with vertebral fractures. It was in the osteoporotic range in 20.1% (n = 23) and the osteopenic range in 40.3% (n = 46). Vertebral fractures were associated with age, duration of hemodialysis, BMI, and femoral neck Z score (R2 37.8%, p = 0.027). Conclusion As incipient vertebral fractures can be observed in patients with normal BMD levels in kidney transplant recipients, conventional X-ray screening for vertebral fractures may be beneficial for a proper therapy decision of metabolic bone disease in kidney transplant recipients.
- 22 January 2022
- Published by Springer Nature in Neuroradiology
- Vol. 64 (7) , 1411-1418
Does concomitant prolactin measurement ıncrease the accuracy of ınferior petrosal sinus sampling?
Introduction Prolactin (PRL) measurement during inferior petrosal sinus sampling (IPSS) can be helpful to improve the accuracy. We aimed to evaluate the effect of measuring PRL levels as a predictor for the accuracy of IPSS and evaluate its impact on the lateralization of adenomas. Methods In this retrospective cohort study, we reviewed 51 patients who had undergone IPSS for the investigation of ACTH-dependent hypercortisolism. Results Forty-nine patients had proven Cushing’s disease (CD), one had EAS, and the remaining one patient had adrenal adenoma. Forty-seven patients had an above 2 ACTH IPS/P ratio at baseline, and all the post-corticotropin-releasing hormone (CRH) ACTH IPS/P ratios of patients with proven CD were above 3. In these two patients whose ACTH IPS/P ratio at baseline was below 2, PRL IPS/P ratios were above 1.8 in only the dominant side, which was considered secondary to a prolactin intersinus gradient due to the biological effects of the tumor. PRL-adjusted ACTH IPS/P ratios were > 1.3 in all patients with proven CD; it was 0.7 in the patient with EAS. Surgically confirmed positive lateralization was observed in 55.1% of patients with the ACTH gradient, but when PRL-adjusted ACTH IPS/IPS ratios were used in addition to the ACTH gradient, the ratio increased to 67.3%. Conclusion Although PRL-adjusted ACTH IPS/P ratios can be helpful to improve the accuracy of results during IPSS procedures, a prolactin intersinus gradient towards the ACTH-dominant side in patients with CD may invalidate PRL as an indicator of pituitary venous outflow.
- 22 January 2022
- Published by Springer Nature in Neuroradiology
- Vol. 64 (7) , 1411-1418
Does concomitant prolactin measurement ıncrease the accuracy of ınferior petrosal sinus sampling?
Introduction Prolactin (PRL) measurement during inferior petrosal sinus sampling (IPSS) can be helpful to improve the accuracy. We aimed to evaluate the effect of measuring PRL levels as a predictor for the accuracy of IPSS and evaluate its impact on the lateralization of adenomas. Methods In this retrospective cohort study, we reviewed 51 patients who had undergone IPSS for the investigation of ACTH-dependent hypercortisolism. Results Forty-nine patients had proven Cushing’s disease (CD), one had EAS, and the remaining one patient had adrenal adenoma. Forty-seven patients had an above 2 ACTH IPS/P ratio at baseline, and all the post-corticotropin-releasing hormone (CRH) ACTH IPS/P ratios of patients with proven CD were above 3. In these two patients whose ACTH IPS/P ratio at baseline was below 2, PRL IPS/P ratios were above 1.8 in only the dominant side, which was considered secondary to a prolactin intersinus gradient due to the biological effects of the tumor. PRL-adjusted ACTH IPS/P ratios were > 1.3 in all patients with proven CD; it was 0.7 in the patient with EAS. Surgically confirmed positive lateralization was observed in 55.1% of patients with the ACTH gradient, but when PRL-adjusted ACTH IPS/IPS ratios were used in addition to the ACTH gradient, the ratio increased to 67.3%. Conclusion Although PRL-adjusted ACTH IPS/P ratios can be helpful to improve the accuracy of results during IPSS procedures, a prolactin intersinus gradient towards the ACTH-dominant side in patients with CD may invalidate PRL as an indicator of pituitary venous outflow.
- 22 January 2022
- Published by Elsevier in Microvascular Research
- Vol. 141, 104323
Capillary microarchitectural changes in Cushing's syndrome
- 22 January 2022
- Published by Elsevier in Microvascular Research
- Vol. 141, 104323
Capillary microarchitectural changes in Cushing's syndrome
- Open Access
- 17 January 2022
- Published by Archives of Endocrinology and Metabolism in Archives of Endocrinology and Metabolism
- Vol. 66 (1) , 32-39
When do we need to suspect maturity onset diabetes of the young in patients with type 2 diabetes mellitus?
Objetivo: Maturity onset diabetes of the young (MODY) patients have clinical heterogeneity as shown by many studies. Thus, often it is misdiagnosed to type 1 or type 2 diabetes(T2DM). The aim of this study is to evaluate MODY mutations in adult T2DM patients suspicious in terms of MODY, and to show clinical and laboratory differences between these two situations. Subjects and methods: In this study, we analyzed 72 type 2 diabetic patients and their relatives (35F/37M) who had been [...] ABSTRACT Objetivo: Maturity onset diabetes of the young (MODY) patients have clinical heterogeneity as shown by many studies. Thus, often it is misdiagnosed to type 1 or type 2 diabetes(T2DM). The aim of this study is to evaluate MODY mutations in adult T2DM patients suspicious in terms of MODY, and to show clinical and laboratory differences between these two situations. Subjects and methods: In this study, we analyzed 72 type 2 diabetic patients and their relatives (35F/37M) who had been
- 17 January 2022
- Published by Archives of Endocrinology and Metabolism in Archives of Endocrinology and Metabolism
- Vol. 66 (1) , 32-39
Open AccessWhen do we need to suspect maturity onset diabetes of the young in patients with type 2 diabetes mellitus?
Objetivo: Maturity onset diabetes of the young (MODY) patients have clinical heterogeneity as shown by many studies. Thus, often it is misdiagnosed to type 1 or type 2 diabetes(T2DM). The aim of this study is to evaluate MODY mutations in adult T2DM patients suspicious in terms of MODY, and to show clinical and laboratory differences between these two situations. Subjects and methods: In this study, we analyzed 72 type 2 diabetic patients and their relatives (35F/37M) who had been [...] ABSTRACT Objetivo: Maturity onset diabetes of the young (MODY) patients have clinical heterogeneity as shown by many studies. Thus, often it is misdiagnosed to type 1 or type 2 diabetes(T2DM). The aim of this study is to evaluate MODY mutations in adult T2DM patients suspicious in terms of MODY, and to show clinical and laboratory differences between these two situations. Subjects and methods: In this study, we analyzed 72 type 2 diabetic patients and their relatives (35F/37M) who had been